Inozyme Pharma, Inc.
INZY
$1.26
-$0.23-15.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.19% | 9.11% | -15.79% | -8.37% | -29.49% |
| Total Depreciation and Amortization | -9.23% | 3.72% | 3.30% | -12.92% | 0.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.19% | 71.89% | 3,771.43% | 63.64% | -115.37% |
| Change in Net Operating Assets | 402.86% | -188.93% | 261.12% | -145.81% | 199.52% |
| Cash from Operations | 21.77% | -3.68% | 3.57% | -32.70% | 2.02% |
| Capital Expenditure | -30.77% | -- | 100.00% | 69.52% | -1,400.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33.83% | 31.12% | 70.88% | 263.80% | 85.73% |
| Cash from Investing | -33.87% | 31.05% | 71.41% | 260.65% | 85.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.55% | 2,197.60% | 188.05% | 893.75% | -99.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.55% | 2,197.60% | 188.05% | -98.73% | -82.05% |
| Foreign Exchange rate Adjustments | -300.00% | 0.00% | -110.00% | -92.54% | 173.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.40% | 273.48% | 61.45% | -13.51% | -303.42% |